Navigation Links
Generex Provides an Overview of its Cancer Immunotherapy Product, AE37, and Potential in Early Breast Cancer Given Current and Potential Future Therapies
Date:1/30/2013

WORCESTER, Mass. and TORONTO, Jan. 30, 2013 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) today provided an overview on the early breast cancer competitive status of the lead cancer immunotherapy product, AE37, under development at its wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com).  A detailed update on development plans will be provided during the previously announced conference call scheduled for Thursday, January 31, 2013.  Antigen Express is in late Phase IIb clinical development for early stage breast cancer that has provided very encouraging interim results and Phase I testing in prostate cancer has been completed.

The specific advantage of the cancer immunotherapy product AE37 is in early breast cancer by potentially stimulating the immune system to target HER2 (the target for Herceptin's effect) on breast cancer cells at low levels independent of immune type of the person. This follows in the footsteps of one of the most successful therapeutics ever developed for breast cancer (Herceptin), though AE37 potentially addresses an early breast cancer patient population of unmet need several times more common than those treated with Herceptin. In particular, while Herceptin is approved for use in roughly 25% of early stage breast cancer patients with high expression of HER2, it is not approved for the larger group of women (50% of women with early breast cancer) who have lower levels of expression of the target for Herceptin (HER2). Rather than attacking HER2 cancer cells directly as does Herceptin, AE37 works by stimulating the immune system to recognize HER2. The greater sensitivity of the immune system can thereby be brought to bear to recognize and kill cancer cells in this larger low HER2 expressing early breast cancer population. An additional pot
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Generex Announces Presentations of Antigen Express AE37 Breast Cancer Vaccine Data at ASCO 2012
2. Generex Announces New Members of Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine
3. Generex Augments Antigen Express Scientific Advisory Board
4. Generex Reports on Inaugural AE37 Breast Cancer Vaccine Scientific Advisory Board Meeting
5. Generex Announces OncUView.tv Interviews Featuring the Antigen Express AE37 Breast Cancer Vaccine at ASCO 2012
6. Generex Announces Results of Annual Stockholders Meeting
7. Generex Addresses Recent Trading Volume in Shares of its Common Stock
8. Generex Announces Details of Investor Conference Call
9. MediPendant™ to Return to Television on May 20th New Television Campaign - Company Provides MediPendant™ Update
10. Anthera Pharmaceuticals Reports 2012 First Quarter Financial Results And Provides Clinical Progress Update
11. Regeneron Provides Update On FDA Advisory Committee Discussion of ARCALYST® (rilonacept) Injection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... Corporation (Nasdaq: DRRX ) announced today financial ... Total revenues were $4.3 million for the three months ... ended December 31, 2013.  Net loss was $5.9 million ... compared to a net loss of $5.1 million for ... and net loss was $22.1 million for the year ...
(Date:3/2/2015)... 2015 Click here for additional information on ... DPLO ), the nation,s largest independent specialty pharmacy, ... 31, 2014. All comparisons, unless otherwise noted, are to the ... Fourth Quarter 2014 Highlights include: , Revenue of ... dispensed of 208,000, an increase of 11% , Gross ...
(Date:3/2/2015)... N.J. , March 2, 2015 BD ... a leading global medical technology company, today announced the ... Diego -based medical technology company dedicated to improving ... acquisition furthers BD,s position in helping address preventable medication ... and CRISI entered into an exclusive partnership in June ...
Breaking Medicine Technology:DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 2DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 3DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 4DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 5DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 6DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 7DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 8DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 9DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 10DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 11DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 12Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 2Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 3Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 4Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 5Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 6Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 7Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 8Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 9Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 10Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 11Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 12Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 13Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 14Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 15Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 16Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 17Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 18Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 19Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 20Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 21BD Acquires CRISI Medical Systems 2BD Acquires CRISI Medical Systems 3
... Reportlinker.com announces that a new market research ... Chinese Pharmaceutical Regulatory Report 2011 ... This report includes a brief ... in China, as well as a discussion ...
... 25, 2011 Reportlinker.com announces that a ... its catalogue: Triple Analysis: ... http://www.reportlinker.com/p0284719/Triple-Analysis-Lymphoma-Prostate-Cancer-and-Antibodies.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology This ... strategies in both Lymphoma and Prostate Cancer ...
Cached Medicine Technology:Reportlinker Adds Chinese Pharmaceutical Regulatory Report 2011 2Reportlinker Adds Triple Analysis: Lymphoma, Prostate Cancer and Antibodies 2Reportlinker Adds Triple Analysis: Lymphoma, Prostate Cancer and Antibodies 3Reportlinker Adds Triple Analysis: Lymphoma, Prostate Cancer and Antibodies 4Reportlinker Adds Triple Analysis: Lymphoma, Prostate Cancer and Antibodies 5
(Date:3/2/2015)... 02, 2015 After a rigorous evaluation ... service, pricing and long-term strategy, Blood Centers of America ... choice for member centers’ testing needs. , BCA, which ... more than 30 percent of the U.S. blood supply, ... “BCA is committed to drive cost savings to members,” ...
(Date:3/2/2015)... 02, 2015 New York singer/songwriter ... be delivering a plenary address entitled Finding the ... Art of Healing and Recovery at this year’s ... Healthcare Executive Summit (BHES).     , With more than ... have been recorded by some of the biggest ...
(Date:3/2/2015)... 02, 2015 Over the last five ... leading vendors seeking to expand their geographic presence and ... expected to reach $6.2 billion by 2019 at CAGR ... including the U.S. and Canada and a major part ... developing regions such as Asia-Pacific including China and India, ...
(Date:3/2/2015)... (PRWEB) March 02, 2015 The ... grow at a CAGR of 6.1% to reach ... 2014. , Factors such as advantages of ... healthcare costs owing to minimally invasive surgeries and ... population are driving the global minimally invasive surgical ...
(Date:3/2/2015)... 2015 LegitScript, LLC, operator ... programs, including those for Internet pharmacy certification, ... and classification, has launched a certification program ... new program, called iCareRx , provides ... the identity of the owner/operator of Internet ...
Breaking Medicine News(10 mins):Health News:Blood Centers of America Chooses QualTex Laboratories as Vendor of Choice 2Health News:Blood Centers of America Chooses QualTex Laboratories as Vendor of Choice 3Health News:Richie Supa Announced as a Plenary Speaker at NCAD 2015 2Health News:Therapeutic Ultrasound Devices Market worth $6.2 Billion by 2019 - New Research Report by MarketsandMarkets 2Health News:Therapeutic Ultrasound Devices Market worth $6.2 Billion by 2019 - New Research Report by MarketsandMarkets 3Health News:Minimally Invasive Surgical Instrument Market - Global Forecast to 2019 - New Report by MarketsandMarkets 2Health News:LegitScript Launches Certification Program for Internet Eyeglass Sellers 2
... Honey is sweeter, has lesser calories, healthful antioxidants and ... table sugar for people who want to lose// weight. ... San Diego State University studied buckwheat honey and clover ... honey from Florida, reported the online edition of the ...
... influences of paternity on the brain, delved into the ... resemblance with humans. Tiny monkeys called marmosets, whose brains ... into how fatherhood can actually instigate changes in ... were structural changes in the brain of the marmoset ...
... myotonic dystrophy in adults, which is the most common type ... // br>,Doctors at the University of Virginia Health System have ... poisonous RNA (ribonucleic acid) in muscle cells could result in ... 40,000 people in the United States have myotonic muscular dystrophy ...
... children who are highly sensitive to allergies in the first ... asthma. // ,Sabina Illi and colleagues at the University ... of exposure to allergens in early life and the effect ... function and asthma. They had reported their findings in the ...
... have succumbed to an outbreak of mosquito-borne encephalitis B in ... in addition to the 26 people already killed by the ... have been infected with the disease and 40 of them ... were detected in the first six months of 2006. But ...
... survey by Australian Bureau of Statistics (ABS) found that the number ... In the new figures released by// ABS, they have noted ... ,About two million Australians were found to be ... men were still more likely to be drinking more, the survey ...
Cached Medicine News:Health News:Toxic Strand Of RNA Causes Myotonic Muscular dystrophy 2Health News:Babies Prone To Allergies More likely To Be Asthmatic 2
Inquire...
Inquire...
Superior Skin Care...Convex FlexWear skin barrier is secure and provides extended weartime. Security and confidence assured with internal non-reflux valves and a drain valve that allows regulation of...
Protects skin from corrosive drainage with the standard wear, FlexWear skin barrier. Security and confidence assured with porous tape, internal non-reflux valves, convenient drain valve....
Medicine Products: